Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and specialty markets. During the year ended December 31, 2008, the Company developed KRYSTEXXA (pegloticase), a therapy for patients with treatment-failure gout (TFG) to control hyperuricemia and to manage the signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning and decreased frequency of flares. The Company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company distributes the branded version of oxandrolone in the United States under the name Oxandrin and its authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. (Watson).